Psoriatic Disease
IMIDs not tied to adverse pregnancy outcomes overall; lupus, APS linked to preterm birth
Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.
FDA approves Simlandi as third interchangeable Humira biosimilar
The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.
New mechanisms, nanobody ‘revolution’ promising for psoriatic arthritis treatment
SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” represent a promising new frontier for psoriatic arthritis, according to a speaker here.
Guselkumab efficacious in biologic-naïve patients with PsA, those unresponsive to TNFi
Guselkumab demonstrates consistent pharmacological effects across both patients naïve to biologics and those with an inadequate response to TNF inhibitors, according data published in Arthritis & Rheumatology.
Conversion initiative gives ‘significant’ boost to Remicade biosimilar use
An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.
Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand
Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.
Early benefit with guselkumab predicts lower psoriatic arthritis progression at 2 years
Among patients with psoriatic arthritis treated with guselkumab, early joint improvement by week 8 predicts lower radiographic progression rates through 2 years, according to data published in Clinical Rheumatology.
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.
Odds of opioid use in autoimmune rheumatic disease decreased 15% annually after 2014
SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.
Tofacitinib improves enthesitis in psoriatic arthritis regardless of baseline severity
Tofacitinib improves enthesitis in patients with psoriatic arthritis regardless of severity or location at baseline, according to data published in Arthritis Research and Therapy.